Disease |
Myeloid malignancies. |
Phenotype / cell stem origin |
Fifteen cases are available (Tien et al., 1989; Henzan et al., 2004; Storlazzi et al., 2004; Madrigal et al., 2006; Bobadilla et al., 2007; Colovic et al., 2011; Haferlach et al., 2012). There were 4 chronic myelogenous leukemia in blast crisis (CML-BC), one myelodysplastic syndrome (MDS) and 10 acute myeloid leukemia (AML) cases. |
Epidemiology | t(3;7)(q26;q21) represented about 1% of a cohort of 606 AML and 377 MDS patients with normal karyotypes (n = 594) or chromosome 7 alterations (-7/7q-; n = 389). Median age was 51 years (range 47-70) (Haferlach et al., 2012). In 6 other patients, ages were, 18, 41, 56, 58, 61 and 71 years. Of 7 cases with data on the patient'sex; there were 6 male and 1 female patient. |
Cytogenetics | Cryptic rearrangement. |
Prognosis | Poor prognosis. Survival outcomes in 22 patients with cryptic MECOM rearrangements (der(7)t(3;7)(q26;q21), inv(3)(p24q26), and t(3;21)(q26;q11), altogether) were compared with inv(3)(q21q26)/t(3;3)(q21;q26) cases. Median overall survival was 9.4 months in the subgroup with cryptic MECOM rearrangements which was not significantly different from the 21.8 months in patients with an inv(3)(q21q26)/t(3;3)(q21;q26) (Haferlach et al., 2012). The 3 other patients with t(3;7)(q26;q21) and survival data died 4, 6, and 26 months after diagnosis. |
An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. |
Bobadilla D, Enriquez EL, Alvarez G, Gaytan P, Smith D, Slovak ML. |
Br J Haematol. 2007 Mar;136(6):806-13. |
PMID 17341266 |
|
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. |
Colović M, Suvajdić N, Janković G, Tomin D, Colović N, Fekete MD, Palibrk V. |
Biomed Pharmacother. 2011 Aug;65(5):319-21. doi: 10.1016/j.biopha.2011.04.006. Epub 2011 Jun 1. |
PMID 21775097 |
|
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. |
Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S. |
Genes Chromosomes Cancer. 2012 Dec;51(12):1079-85. doi: 10.1002/gcc.21992. Epub 2012 Aug 8. |
PMID 22887804 |
|
Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia. |
Henzan H, Yoshimoto G, Okeda A, Nagasaki Y, Hirano G, Takase K, Tanimoto T, Miyamoto T, Fukuda T, Nagafuji K, Harada M. |
Ann Hematol. 2004 Dec;83(12):784-8. Epub 2004 Aug 18. |
PMID 15322764 |
|
Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements. |
Madrigal I, Carrió A, Gómez C, Rozman M, Esteve J, Nomdedeu B, Campo E, Costa D. |
Cancer Genet Cytogenet. 2006 Oct 15;170(2):115-20. |
PMID 17011981 |
|
A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. |
Storlazzi CT, Anelli L, Albano F, Zagaria A, Ventura M, Rocchi M, Panagopoulos I, Pannunzio A, Ottaviani E, Liso V, Specchia G. |
Ann Hematol. 2004 Feb;83(2):78-83. Epub 2003 Oct 10. |
PMID 14551738 |
|
Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan. |
Tien HF, Chuang SM, Wang CH, Lee FY, Chien SH, Chen YC, Shen MC, Liu CH. |
Cancer Genet Cytogenet. 1989 May;39(1):89-97. |
PMID 2731152 |
|
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. |
Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V. |
Oncogene. 2016 Jun 16;35(24):3083-91. doi: 10.1038/onc.2015.407. Epub 2015 Oct 26. Review. |
PMID 26500059 |
|
inv(3)(q21q26)x2 |
de Braekeleer E, Douet-Guilbert, N, Le Bris MJ, Basink A, Morel F, de Braekeleer M. |
Atlas Genet Cytogenet Oncol Haematol. 2013;17(7):491-493. |
|